Balamurali Ambati is an Ophthalmology physician affiliated with University of Oregon. OpenAlex indexes 255 publications with 12,190 citations (h-index 50); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients
Sponsor: iVeena Delivery Systems, Inc.
- Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking
Sponsor: Pacific Clear Vision Institute
- Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
Sponsor: University of Utah
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
70.1%Prostaglandin Analog35.5%Latanoprost100%Part D≥56 patientsCorticosteroid17.3%Prednisolone Acetate100%Part D≥60 patients+ 3 more classes in this area
Cardiovascular
10.8%Beta blocker10.8%Timolol Maleate100%Part D≥21 patientsNervous system
8.4%Cholinergic Receptor Agonist6.5%Pilocarpine Hcl100%Part D<11 patientsOpioid Agonist1.9%Oxycodone-Acetaminophen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2021 per NIH RePORTER. The latest:
- NEUROVASCULAR CROSS-TALK, FUNCTIONS AND SOURCES OF SOLUBLE VEGF RECEPTORS IN OCULAR VASCULAR DEMARCATION
University of Oregon
FY2021$357,688R01EY017950 - Neurovascular Cross-Talk, Functions and Sources of Soluble VEGF Receptors in Ocular Vascular Demarcation
University of Oregon
FY2020$330,393R01EY017950
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”